Author:
Fukushima Toshihiro,Yamashita Taro,Goto Nobuyuki,Ueda Takanori,Okabe Ken-ichi,Kuraishi Yasunobu,Ohno Ryuzo,Urabe Akio,Ogawa Makoto
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Arcamone F, Bernardi L, Giardino P, et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicin, and their β anomers.Cancer Treat Rep. 1976;60:829–834.
2. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.Blood. 1991;77:1666–1674.
3. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.J Clin Oncol. 1992;10:1103–1111.
4. Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.Blood. 1992;79:313–319.
5. Bassan R, Di Bona E, Lerede T, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.Leuk Lymph. 1996;22:295–301.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献